VectorY Strengthens Leadership with New CEO

VectorY Therapeutics, a biotechnology firm innovating in the field of neurodegenerative disease treatment, has made significant strategic advancements with the appointment of Jim Scibetta as its new CEO. The former CEO, Sander van Deventer, has transitioned to the role of President of R&D, continuing his focus on advancing the company's pipeline, particularly the lead program VTx-002 designed for treating Amyotrophic Lateral Sclerosis (ALS). This strategic leadership change coincides with the expansion of VectorY's corporate presence into the United States, specifically Boston. The appointment follows the firm's $138 million Series A funding round, bolstered by the support of EQT Life Sciences and Forbion. This funding is intended to advance VTx-002 into clinical trials and further preclinical development efforts. VectorY's technology is noted for its potential in addressing the underlying pathological drivers of ALS by targeting TDP-43, aiming to delay the disease's progression and improve patient quality of life. With favorable feedback from the FDA on its preclinical data, VectorY is poised for significant advancements under Scibetta's leadership.